Athmar Dhahir Habeeb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Athmar Dhahir Habeeb has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ashti M H Saeed
Department of Pharmaceutics, College of Pharmacy, Mustansiriyah University, Baghdad, 10011, Iraq
1 shared publication - Maryam Alaayedi
Department of Pharmaceutics, College of Pharmacy, University of Kerbala, Kerbala, Iraq
1 shared publication Peng T. Khaw
National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, EC1V 9EL, UK
1 shared publication- Sahar Awwad
Optceutics Ltd., 28a Menelik Road, London NW2 3RP, UK
1 shared publication - Sarah Sabah Sabah Muter
Mustansiriyah University, Baghdad, Iraq
1 shared publication - Steve Brocchini
UCL School of Pharmacy
1 shared publication
Latest Publications
- Open Access
- 14 May 2025
- Published by Pensoft Publishers in Pharmacia
- Vol. 72, 1-12
Preparation and evaluation of gastroretentive floating unfolding film of baclofen
Baclofen, a muscle relaxant used for severe pain management, has a narrow absorption window limiting its bioavailability. Enhancing its gastric residence time could potentially improve its absorption and effectiveness. Floating drug delivery systems are a promising approach to prolong drug retention in the stomach. This study aimed to develop a floating bilayer film for the sustained release of baclofen. The core of the film was formulated with baclofen, PVP K90, sodium alginate, and PEG 400 as a plasticizer, while the controlled release layer contained Eudragit RS100 or RLPO with different plasticizers (DBP and PEG 400). All formulations were evaluated for weight uniformity, drug content, thickness, folding ability, swelling, and in vitro drug release. The optimized formula had a 98% drug release within 12 hours, floated effectively for 24 hours, and followed zero-order kinetics.
- 14 May 2025
- Published by Pensoft Publishers in Pharmacia
- Vol. 72, 1-12
Open AccessPreparation and evaluation of gastroretentive floating unfolding film of baclofen
Baclofen, a muscle relaxant used for severe pain management, has a narrow absorption window limiting its bioavailability. Enhancing its gastric residence time could potentially improve its absorption and effectiveness. Floating drug delivery systems are a promising approach to prolong drug retention in the stomach. This study aimed to develop a floating bilayer film for the sustained release of baclofen. The core of the film was formulated with baclofen, PVP K90, sodium alginate, and PEG 400 as a plasticizer, while the controlled release layer contained Eudragit RS100 or RLPO with different plasticizers (DBP and PEG 400). All formulations were evaluated for weight uniformity, drug content, thickness, folding ability, swelling, and in vitro drug release. The optimized formula had a 98% drug release within 12 hours, floated effectively for 24 hours, and followed zero-order kinetics.
- Open Access
- 1 February 2018
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- Vol. 11 (2) , 308-312
NEW COMBINATION SUPPOSITORIES OF LORNOXICAM AND ALOIN FOR RHEUMATOID ARTHRITIS
Objective: The objective of our current work is to formulate, optimize and evaluate new combination rectal suppositories as a treatment for rheumatoid arthritis that contains both lornoxicam and aloin. Both are strong anti-inflammatory agents, and a combination of both may have synergistic effect as an anti-inflammatory treatment.Methods: Rectal suppositories containing 8 mg lornoxicam and 200 mg aloin were formulated by heat fusion method. Different combinations of different molecular weights of polyethylene glycol (PEG) were used for the formulated suppositories. The formulated suppositories were evaluated for their visual appearance, weight variation, hardness, friability, disintegration time, melting temperature, and drug content uniformity.Results: All the formulations prepared were within the required limits for USP. When the release study was performed, both drugs were released from all the formulations prepared. However, formulation F7 which is composed of PEG 400 30.88% (w/w): PEG 4000 46.32% (w/w) was superior to other formulations in which more than 80% of both drugs loaded were released after 35 min. The presence of both drugs in the same suppository did not affect their release.Conclusion: A new combination suppositories have been obtained where the two combined drugs were released fast without interference with each other release. The proposed new combination has the potential to be used as a strong analgesic and anti-inflammatory treatment compared to using lornoxicam or aloin alone.
- 1 February 2018
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- Vol. 11 (2) , 308-312
Open AccessNEW COMBINATION SUPPOSITORIES OF LORNOXICAM AND ALOIN FOR RHEUMATOID ARTHRITIS
Objective: The objective of our current work is to formulate, optimize and evaluate new combination rectal suppositories as a treatment for rheumatoid arthritis that contains both lornoxicam and aloin. Both are strong anti-inflammatory agents, and a combination of both may have synergistic effect as an anti-inflammatory treatment.Methods: Rectal suppositories containing 8 mg lornoxicam and 200 mg aloin were formulated by heat fusion method. Different combinations of different molecular weights of polyethylene glycol (PEG) were used for the formulated suppositories. The formulated suppositories were evaluated for their visual appearance, weight variation, hardness, friability, disintegration time, melting temperature, and drug content uniformity.Results: All the formulations prepared were within the required limits for USP. When the release study was performed, both drugs were released from all the formulations prepared. However, formulation F7 which is composed of PEG 400 30.88% (w/w): PEG 4000 46.32% (w/w) was superior to other formulations in which more than 80% of both drugs loaded were released after 35 min. The presence of both drugs in the same suppository did not affect their release.Conclusion: A new combination suppositories have been obtained where the two combined drugs were released fast without interference with each other release. The proposed new combination has the potential to be used as a strong analgesic and anti-inflammatory treatment compared to using lornoxicam or aloin alone.
- 4 December 2017
- Published by Wiley in Macromolecular Bioscience
- Vol. 18 (2)
Comparative Study of In Situ Loaded Antibody and PEG‐Fab NIPAAM Gels
Hydrogels can potentially prolong the release of a therapeutic protein, especially to treat blinding conditions. One challenge is to ensure that the protein and hydrogel are intimately mixed by better protein entanglement within the hydrogel. N‐isopropylacrylamide (NIPAAM) gels are optimized with poly(ethylene glycol) diacrylate (PEDGA) crosslinker in the presence of either bevacizumab or PEG conjugated ranibizumab (PEG10‐Fabrani). The release profiles of the hydrogels are evaluated using an outflow model of the eye, which is previously validated for human clearance of proteins. Release kinetics of in situ loaded bevacizumab‐NIPAAM gels displays a prolonged bimodal release profile in phosphate buffered saline compared to bevacizumab loaded into a preformed NIPAAM gel. Bevacizumab release in simulated vitreous from in situ loaded gels is similar to bevacizumab control indicating that diffusion through the vitreous rather than from the gel is rate limiting. Ranibizumab is site‐specifically PEGylated by disulfide rebridging conjugation. Prolonged and continuous release is observed with the in situ loaded PEG10‐Fabrani‐NIPAAM gels compared to PEG10‐Fabrani injection (control). Compared to an unmodified protein, there is better mixing due to PEG entanglement and compatibility of PEG10‐Fabrani within the NIPAAM‐PEDGA hydrogel. These encouraging results suggest that the extended release of PEGylated proteins in the vitreous can be achieved using injectable hydrogels.
- 4 December 2017
- Published by Wiley in Macromolecular Bioscience
- Vol. 18 (2)
Comparative Study of In Situ Loaded Antibody and PEG‐Fab NIPAAM Gels
Hydrogels can potentially prolong the release of a therapeutic protein, especially to treat blinding conditions. One challenge is to ensure that the protein and hydrogel are intimately mixed by better protein entanglement within the hydrogel. N‐isopropylacrylamide (NIPAAM) gels are optimized with poly(ethylene glycol) diacrylate (PEDGA) crosslinker in the presence of either bevacizumab or PEG conjugated ranibizumab (PEG10‐Fabrani). The release profiles of the hydrogels are evaluated using an outflow model of the eye, which is previously validated for human clearance of proteins. Release kinetics of in situ loaded bevacizumab‐NIPAAM gels displays a prolonged bimodal release profile in phosphate buffered saline compared to bevacizumab loaded into a preformed NIPAAM gel. Bevacizumab release in simulated vitreous from in situ loaded gels is similar to bevacizumab control indicating that diffusion through the vitreous rather than from the gel is rate limiting. Ranibizumab is site‐specifically PEGylated by disulfide rebridging conjugation. Prolonged and continuous release is observed with the in situ loaded PEG10‐Fabrani‐NIPAAM gels compared to PEG10‐Fabrani injection (control). Compared to an unmodified protein, there is better mixing due to PEG entanglement and compatibility of PEG10‐Fabrani within the NIPAAM‐PEDGA hydrogel. These encouraging results suggest that the extended release of PEGylated proteins in the vitreous can be achieved using injectable hydrogels.